3D human sebaceous glands technology for skin care applications

New 3D technology provides a powerful platform for skin care researchers wishing to study the function of sebaceous glands, in relation to a range of age-related, microbial and inflammatory skin disorders.

At NYSCC Cosmetic Congress, BASF Care Creations and the Cell Therapy Research Institute CTIBiotech presented the initial results of their joint research on 3D tissue models for the development and testing of bio-actives for skin care applications: After 2 years of research, the experts have now demonstrated both the ex vivo production of physiological sebum in a long-term culture of a 3D human sebaceous gland model, and the regulation of this sebum production by means of active ingredients.

3D human sebaceous glands technology for skin care applications

Using CTIBiotech’s 3D human sebaceous gland technology, scientists were able to improve BASF’s 3D skin model portfolio. The new 3D technology provides a powerful platform for skin care researchers wishing to study the function of sebaceous glands, in relation to a range of age-related, microbial and inflammatory skin disorders.

“Working with BASF allowed us to validate a powerful technology for human skin care research in very little time,” said Dr. Nico Forraz, Chief Executive Officer at CTIBiotech. “This positions CTIBiotech as a world leader in innovative and even disruptive technologies for human cell-based bioassays, applied to dermo-cosmetics.”

“Compared to current in vitro methods, the 3D models developed by CTIBiotech allow analysis more in touch with human physiology and sebaceous gland metabolism,” said BASF’s project lead Dr Sabine Pain. “That’s how their technology helps us accelerate the development of innovative and highly reliable ingredients for the skin care market. Our understanding of sebaceous gland metabolism provides the basis for developing and testing advanced cosmetic bio-actives for skin care applications, and in particular skincare products for oily skin.”

“Because of their experience and expertise in developing solutions for the dermo-cosmetics market, BASF understands the benefits of collaborating with tissue engineering experts,” added Professor Colin McGuckin, Chief Scientific Officer and President of CTIBiotech. “The next evolution of the sebaceous gland model will be based on a 3D bio-printing technology that allows us to fully reproduce micro-glands into a full thickness skin model, in vitro.”

Read More



Other news in “Research & Development”

New automated VPT systems for topical drug performance testing

New automated VPT systems for topical drug performance testing 

11 Jan 2018
Sangamo and Pfizer collaborate to develop zinc finger protein gene therapy for ALS

Sangamo and Pfizer collaborate to develop zinc finger protein gene therapy for ALS 

7 Jan 2018
Momenta and Mylan to development proposed biosimilar to Eylea

Momenta and Mylan to development proposed biosimilar to Eylea 

4 Jan 2018